Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

NCT06881784 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT06881784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06881784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
May 6, 2025
Completion date
December 1, 2030
Enrollment
590 (estimated)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, nsclc, nsclc (advanced non-small cell lung cancer), nsclc (non-small cell lung cancer), nsclc (non-small cell lung carcinoma)